Trials / Terminated
TerminatedNCT00210392
VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy
Phase II Study of VELCADE in Patients With Extranodal Marginal Zone B-Cell Lymphoma of MALT-Type Pretreated With More Than One Prior Systemic Therapy Regimen (X05142)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG) · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the antitumor activity (in terms of overall response rate - ORR - i.e. sum of complete and partial responses) of bortezomib in pretreated MALT lymphomas with more than one prior systemic therapy regimen
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bortezomib (drug) | Bortezomib 1,3 mg/m2 iv d1,4,8,11 every 21 days. Total 6 cycles |
Timeline
- Start date
- 2005-07-01
- Primary completion
- 2007-11-01
- Completion
- 2007-11-01
- First posted
- 2005-09-21
- Last updated
- 2015-03-30
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00210392. Inclusion in this directory is not an endorsement.